S.M. Tolaney

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

S.M. Tolaney
Jan 28, 2025, 15:01 | Insight
Breast Cancer Research Digest by Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X: "Check out the Breast Cancer Research Digest…
Jan 19, 2025, 14:07 | Insight
Aleix Prat: Utility of the HER2DX genomic assay in predicting pCR in HER2+ stage III IBC
Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, shared a…
Dec 21, 2024, 12:45 | Insight
Practical treatment strategies and novel therapies for HR positive/HER2 negative advanced breast cancer
Neil Vasan, Breast oncologist at Herbert Irving Comprehensive Cancer Center, shared a post on X:…
Nov 13, 2024, 11:56 | Blog
HER2-Low Status and Its Impact on Outcomes in Early-Stage Triple-Negative Breast Cancer
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared a post on X:…
Sep 19, 2024, 15:18 | Insight
Paolo Tarantino: Monitoring ADC-related interstitial lung disease
Paolo Tarantino shared a post on LinkedIn: "More sensitive ways are needed to monitor for ADC-related…
Sep 7, 2024, 11:16 | Drugs
Paolo Tarantino: Recommended read on adjuvant ribociclib in preparation for the ESMO24
Oncology Brothers shared a post by Paolo Tarantino on X, adding: “Adjuvant abemaciclib preferred for…
Sep 7, 2024, 10:06 | Blog
Is adjuvant ribociclib ready for prime time?
Sarah Sammons shared a post by Paolo Tarantino, on X: "The number needed to treat (NNT) to…
Sep 6, 2024, 11:25 | Insight
Paolo Tarantino: Interesting RWA of outcomes with chemotherapy in HR+/HER2- MBC
Paolo Tarantino shared a post by ESMO Open on X, adding: "Interesting real world analysis…
All: 8 Posts: 1 - 100
Special Coverage